Literature DB >> 22723510

Finasteride and prostate cancer: a commentary.

Channing J Paller1, Thomas J Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22723510      PMCID： PMC3399642          DOI： 10.1634/theoncologist.2012-0165

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  17 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

2.  Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.

Authors:  Bruce E Hillner; Thomas J Smith
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

3.  Limits on Medicare's ability to control rising spending on cancer drugs.

Authors:  Peter B Bach
Journal:  N Engl J Med       Date:  2009-01-27       Impact factor: 91.245

4.  The cost of prostate cancer chemoprevention: a decision analysis model.

Authors:  Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

5.  Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.

Authors:  Steven B Zeliadt; Ruth D Etzioni; David F Penson; Ian M Thompson; Scott D Ramsey
Journal:  Am J Med       Date:  2005-08       Impact factor: 4.965

6.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

7.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

8.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

9.  Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.

Authors:  Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860

Review 10.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Clin Oncol       Date:  2009-02-24       Impact factor: 44.544
View more
  1 in total

1.  SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.

Authors:  Suruchi Aggarwal; Minu Singh; Ashok Kumar; Tapas Mukhopadhyay
Journal:  Mol Cell Biochem       Date:  2015-06-20       Impact factor: 3.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.